Initiation of Phase 1 clinical trial of SBI-100 ophthalmic nanemulsion expected in second the quarter of 2022 SAN DIEGO, CA, February 16, 2022 (GLOBE NEWSWIRE) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced that... Read more